 <h1>Symfi Lo Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>efavirenz / lamivudine / tenofovir</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about efavirenz / lamivudine / tenofovir. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Symfi Lo.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to efavirenz/lamivudine/tenofovir: oral tablet</i></p><h3>Warning</h3><p class="blackboxWarning-title">Oral route (Tablet)</p><p>Warning: Post treatment acute exacerbation of hepatitis BSevere acute exacerbations of hepatitis B have been reported in patients who are co-infected with hepatitis B virus (HBV) and human immunodeficiency virus (HIV-1) and have discontinued lamivudine or tenofovir disoproxil fumarate, two components of efavirenz / lamivudine / tenofovir disoproxil fumarate oral tablets. Monitor hepatic function closely in these patients and, if appropriate, initiate anti-hepatitis B treatment.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, efavirenz / lamivudine / tenofovir may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking efavirenz / lamivudine / tenofovir:</p><p>
<i>More common</i>
</p><ul>
<li>Anxiety</li>
<li>discouragement</li>
<li>feeling sad or empty</li>
<li>fever</li>
<li>irritability</li>
<li>lack of appetite</li>
<li>loss of interest or pleasure</li>
<li>rash</li>
<li>stomach pain</li>
<li>trouble concentrating</li>
<li>trouble sleeping</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Body aches or pain</li>
<li>burning, numbness, tingling, or painful sensations</li>
<li>chest pain</li>
<li>chills</li>
<li>cough</li>
<li>diarrhea</li>
<li>difficulty in moving</li>
<li>ear congestion</li>
<li>headache</li>
<li>joint pain</li>
<li>loss of voice</li>
<li>muscle cramp, pain, or stiffness</li>
<li>nausea</li>
<li>painful blisters on the trunk of the body</li>
<li>runny or stuffy nose</li>
<li>sneezing</li>
<li>sore throat</li>
<li>swollen joints</li>
<li>tightness in the chest</li>
<li>troubled breathing</li>
<li>unsteadiness or awkwardness</li>
<li>unusual tiredness or weakness</li>
<li>weakness in the arms, hands, legs, or feet</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Agitation</li>
<li>blistering, peeling, loosening of the skin</li>
<li>bloating</li>
<li>bone fractures, especially of the femur</li>
<li>bone pain</li>
<li>dark urine</li>
<li>decreased appetite</li>
<li>decreased awareness or responsiveness</li>
<li>decreased urine</li>
<li>difficulty having a bowel movement (stool)</li>
<li>dizziness</li>
<li>dry mouth</li>
<li>fast, irregular heartbeat</li>
<li>fast, shallow breathing</li>
<li>general feeling of discomfort</li>
<li>general feeling of tiredness or weakness</li>
<li>hostility</li>
<li>increased thirst</li>
<li>indigestion</li>
<li>itching</li>
<li>light-colored stools</li>
<li>loss of bone mineral density</li>
<li>loss of consciousness</li>
<li>mood changes</li>
<li>muscle twitching</li>
<li>pains in the stomach, side, or abdomen, possibly radiating to the back</li>
<li>rapid weight gain</li>
<li>red skin lesions, often with a purple center</li>
<li>red, irritated eye</li>
<li>seizures</li>
<li>severe sleepiness</li>
<li>sleepiness</li>
<li>sores, ulcers, or white spots in the mouth or on the lips</li>
<li>stomach discomfort</li>
<li>stomach pain, continuing</li>
<li>swelling of the face, ankles, or hands</li>
<li>upper right abdominal or stomach pain</li>
<li>vomiting</li>
<li>yellow eyes or skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of efavirenz / lamivudine / tenofovir may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Back pain</li>
<li>lack or loss of strength</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Abnormal dreams</li>
<li>belching</li>
<li>heartburn</li>
<li>indigestion</li>
<li>redistribution or accumulation of body fat</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to efavirenz / lamivudine / tenofovir: oral tablet</i></p><h3>General</h3><p>In a controlled trial with efavirenz, lamivudine, and tenofovir disoproxil fumarate (DF), the most common side effects were mild-to-moderate gastrointestinal events and dizziness.  Mild side effects (grade 1) were common and included dizziness, diarrhea, and nausea.</p>
<p></p>
<p>In a controlled trial with efavirenz (400 or 600 mg) in combination with fixed-dose emtricitabine-tenofovir DF, the most common side effects were mild-to-moderate gastrointestinal events, dizziness, abnormal dreams, and rash.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (14%)</p>
<p><b>Common</b> (1% to 10%): Dizziness</p>
<p><b>Uncommon</b> (0.1% to 1%): Peripheral neuropathy (included peripheral neuritis, neuropathy)</p>
<p></p>
<p>Efavirenz (with emtricitabine-tenofovir DF):</p>
<p>-Very common (10% or more): Dizziness (up to 35%), headache (up to 11%)</p>
<p>-Common (1% to 10%): Herpes zoster, somnolence</p>
<p></p>
<p>Efavirenz:</p>
<p>-Very common (10% or more): Central nervous system symptoms (53%), dizziness (28.1%)</p>
<p>-Common (1% to 10%): Impaired concentration, somnolence</p>
<p>-Postmarketing reports: Abnormal coordination, ataxia, cerebellar coordination and balance disturbances, convulsions, hypoesthesia, paresthesia, neuropathy, tremor, vertigo, tinnitus<sup>[Ref]</sup></p><p>Central nervous system (CNS) symptoms were reported in 53% of patients using efavirenz; these symptoms generally began the first or second day of therapy and often resolved after 2 to 4 weeks.  CNS symptoms (any grade, regardless of causality) included, but were not limited to, dizziness, insomnia, impaired concentration, somnolence, abnormal dreams, and hallucinations.  These symptoms were severe in 2% of patients; therapy was discontinued in 2.1% of patients due to these side effects.  After 4 weeks of therapy, CNS symptoms of at least moderate severity were reported in 5% to 9% of patients using efavirenz-containing regimens.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash event (included rash, pruritus, maculopapular rash, urticaria, vesiculobullous rash, pustular rash; 18%)</p>
<p></p>
<p>Efavirenz (with emtricitabine-tenofovir DF):</p>
<p>-Very common (10% or more): Rash event (included allergic dermatitis, drug hypersensitivity, generalized pruritus, eosinophilic pustular folliculitis, rash, erythematous rash, generalized rash, macular rash, maculopapular rash, morbilliform rash, papular rash, pruritic rash, vesicular rash, urticaria; up to 32%)</p>
<p>-Common (1% to 10%): Grade 3 to 4 rash</p>
<p></p>
<p>Efavirenz:</p>
<p>-Very common (10% or more): New-onset skin rash (26%)</p>
<p>-Uncommon (0.1% to 1%): Rash associated with blistering/moist desquamation/ulceration, grade 4 rash (e.g., erythema, multiforme, Stevens-Johnson syndrome)</p>
<p>-Postmarketing reports: Erythema multiforme, photoallergic dermatitis, Stevens-Johnson syndrome</p>
<p></p>
<p>Lamivudine:</p>
<p>-Postmarketing reports: Urticaria, alopecia, pruritus</p>
<p></p>
<p>Tenofovir DF:</p>
<p>-Postmarketing reports: Rash<sup>[Ref]</sup></p><p>Rashes associated with efavirenz were usually mild-to-moderate maculopapular skin eruptions.  The median time to onset of rash was 11 days.  In most patients who continued therapy, the rash resolved within 1 month.  Treatment was discontinued due to rash in 1.7% of patients.<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Elevated fasting cholesterol (19%)</p>
<p><b>Uncommon</b> (0.1% to 1%): Lipodystrophy, elevated fasting triglycerides</p>
<p><b>Frequency not reported</b>: Higher 1,25 vitamin D levels</p>
<p></p>
<p>Efavirenz (with emtricitabine-tenofovir DF):</p>
<p>-Common (1% to 10%): Cholesterol abnormal</p>
<p></p>
<p>Efavirenz:</p>
<p>-Postmarketing reports: Hypercholesterolemia, hypertriglyceridemia, redistribution/accumulation of body fat</p>
<p></p>
<p>Lamivudine:</p>
<p>-Postmarketing reports: Hyperglycemia, lactic acidosis, redistribution/accumulation of body fat</p>
<p></p>
<p>Tenofovir DF:</p>
<p>-Postmarketing reports: Lactic acidosis, hypokalemia, hypophosphatemia</p>
<p></p>
<p>Combination antiretroviral therapy:</p>
<p>-Frequency not reported: Redistribution/accumulation of body fat (including central obesity, dorsocervical fat enlargement, peripheral wasting, facial wasting, breast enlargement, "cushingoid appearance")<sup>[Ref]</sup></p><p>Elevated fasting cholesterol (greater than 240 mg/dL) and fasting triglycerides (greater than 750 mg/dL) have been reported in 19% and 1% of patients using efavirenz, lamivudine, and tenofovir DF, respectively.</p>
<p></p>
<p>Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) have been reported with the use of nucleoside analogs.</p>
<p></p>
<p>Hypokalemia and hypophosphatemia may occur as a result of proximal renal tubulopathy.<sup>[Ref]</sup></p><h3>Other</h3><p>False-positive urine cannabinoid test results have been observed with some screening assays in uninfected and HIV-infected subjects using efavirenz.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Pain (13%)</p>
<p><b>Common</b> (1% to 10%): Fever, asthenia</p>
<p></p>
<p>Efavirenz (with emtricitabine-tenofovir DF):</p>
<p>-Common (1% to 10%): Pyrexia, phosphorus abnormal</p>
<p></p>
<p>Efavirenz:</p>
<p>-Frequency not reported: False-positive urine cannabinoid test results</p>
<p>-Postmarketing reports: Asthenia, flushing</p>
<p></p>
<p>Lamivudine:</p>
<p>-Postmarketing reports: Weakness</p>
<p></p>
<p>Tenofovir DF:</p>
<p>-Postmarketing reports: Asthenia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Elevated creatine phosphokinase (12%)</p>
<p><b>Common</b> (1% to 10%): Back pain, arthralgia, myalgia</p>
<p><b>Frequency not reported</b>: Decreased bone mineral density, increased biochemical markers of bone metabolism (serum bone-specific alkaline phosphatase, serum osteocalcin, serum C telopeptide, urinary N telopeptide), clinically relevant fractures (excluding fingers and toes)</p>
<p></p>
<p>Efavirenz:</p>
<p>-Postmarketing reports: Arthralgia, myalgia, myopathy</p>
<p></p>
<p>Lamivudine:</p>
<p>-Postmarketing reports: Muscle weakness, elevated creatine phosphokinase, rhabdomyolysis</p>
<p></p>
<p>Tenofovir DF:</p>
<p>-Postmarketing reports: Rhabdomyolysis, osteomalacia (manifested as bone pain and which may contribute to fractures), muscular weakness, myopathy<sup>[Ref]</sup></p><p>Elevated creatine phosphokinase (males: greater than 990 units/L; females: greater than 845 units/L) has been reported in 12% of patients using efavirenz, lamivudine, and tenofovir DF.</p>
<p></p>
<p>Rhabdomyolysis, osteomalacia, muscular weakness, and myopathy may occur as a result of proximal renal tubulopathy.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (11%)</p>
<p><b>Common</b> (1% to 10%): Nausea, increased serum amylase, abdominal pain, dyspepsia, vomiting</p>
<p></p>
<p>Efavirenz (with emtricitabine-tenofovir DF):</p>
<p>-Common (1% to 10%): Diarrhea, vomiting, gastroenteritis</p>
<p></p>
<p>Efavirenz:</p>
<p>-Postmarketing reports: Constipation, malabsorption</p>
<p></p>
<p>Lamivudine:</p>
<p>-Frequency not reported: Pancreatitis</p>
<p></p>
<p>Tenofovir DF:</p>
<p>-Postmarketing reports: Pancreatitis, increased amylase, abdominal pain<sup>[Ref]</sup></p><p>Increased serum amylase (greater than 175 units/L) has been reported in 9% of patients using efavirenz, lamivudine, and tenofovir DF.</p>
<p></p>
<p>Pancreatitis (some cases fatal) has been reported in antiretroviral nucleoside-experienced pediatric patients using lamivudine alone or in combination with other antiretroviral agents.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Depression (11%)</p>
<p><b>Common</b> (1% to 10%): Anxiety, insomnia, abnormal dreams</p>
<p></p>
<p>Efavirenz (with emtricitabine-tenofovir DF):</p>
<p>-Common (1% to 10%): Insomnia, abnormal dreams, depression, sleep disorder, nightmare, anxiety</p>
<p></p>
<p>Efavirenz:</p>
<p>-Very common (10% or more): Insomnia (16.3%)</p>
<p>-Common (1% to 10%): Severe depression, abnormal dreams, hallucinations</p>
<p>-Uncommon (0.1% to 1%): Suicidal ideation, nonfatal suicide attempts, aggressive behavior, paranoid reactions, manic reactions</p>
<p>-Postmarketing reports: Aggressive reactions, agitation, delusions, emotional lability, mania, neurosis, paranoia, psychosis, suicide, catatonia<sup>[Ref]</sup></p><h3>Genitourinary</h3><p>Hematuria (greater than 100 RBC/high power field) has been reported in 7% of patients using efavirenz, lamivudine, and tenofovir DF.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Hematuria</p>
<p></p>
<p>Tenofovir DF:</p>
<p>-Postmarketing reports: Proteinuria, polyuria<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Elevated AST (males: greater than 180 units/L; females: greater than 170 units/L) and ALT (males: greater than 215 units/L; females: greater than 170 units/L) have been reported in 5% and 4% patients using efavirenz, lamivudine, and tenofovir DF, respectively.</p>
<p></p>
<p>Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) have been reported with the use of nucleoside analogs.</p>
<p></p>
<p>Severe acute exacerbations of hepatitis B have been reported in patients coinfected with HIV-1 and hepatitis B virus after discontinuation of lamivudine or tenofovir DF.</p>
<p></p>
<p>Hepatic decompensation (some fatal) has been reported in patients coinfected with HIV-1 and hepatitis C receiving combination antiretroviral therapy for HIV-1 and interferon alfa with or without ribavirin.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Elevated AST, elevated ALT</p>
<p></p>
<p>Efavirenz (with emtricitabine-tenofovir DF):</p>
<p>-Common (1% to 10%): ALT abnormal, AST abnormal</p>
<p>-Uncommon (0.1% to 1%): Bilirubin abnormal</p>
<p></p>
<p>Efavirenz:</p>
<p>-Postmarketing reports: Increased hepatic enzymes, hepatic failure, hepatitis (including fulminant hepatitis progressing to liver failure requiring transplantation or resulting in death)</p>
<p></p>
<p>Lamivudine:</p>
<p>-Postmarketing reports: Hepatic steatosis, posttreatment exacerbation of hepatitis B</p>
<p></p>
<p>Tenofovir DF:</p>
<p>-Postmarketing reports: Hepatic steatosis, hepatitis, increased liver enzymes (most commonly AST, ALT, GGT)</p>
<p></p>
<p>Combination antiretroviral therapy:</p>
<p>-Frequency not reported: Hepatic decompensation<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Decreased neutrophils (less than 750/mm3) has been reported in 3% of patients using efavirenz, lamivudine, and tenofovir DF.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Decreased neutrophils</p>
<p></p>
<p>Efavirenz (with emtricitabine-tenofovir DF):</p>
<p>-Common (1% to 10%): Neutrophils abnormal</p>
<p></p>
<p>Lamivudine:</p>
<p>-Postmarketing reports: Anemia (including pure red cell aplasia and severe anemias progressing on therapy)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Pneumonia</p>
<p></p>
<p>Efavirenz (with emtricitabine-tenofovir DF):</p>
<p>-Common (1% to 10%): Upper respiratory tract infection, nasopharyngitis</p>
<p></p>
<p>Efavirenz:</p>
<p>-Postmarketing reports: Dyspnea</p>
<p></p>
<p>Tenofovir DF:</p>
<p>-Postmarketing reports: Dyspnea<sup>[Ref]</sup></p><h3>Renal</h3><p>Tenofovir DF:</p>
<p>-Postmarketing reports: Renal insufficiency, acute renal failure, renal failure, acute tubular necrosis, Fanconi syndrome, proximal renal tubulopathy, interstitial nephritis (including acute cases), nephrogenic diabetes insipidus, increased creatinine<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Efavirenz:</p>
<p>-Postmarketing reports: Allergic reactions</p>
<p></p>
<p>Lamivudine:</p>
<p>-Postmarketing reports: Anaphylaxis</p>
<p></p>
<p>Tenofovir DF:</p>
<p>-Postmarketing reports: Allergic reaction (including angioedema)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Efavirenz:</p>
<p>-Frequency not reported: QTc prolongation</p>
<p>-Postmarketing reports: Palpitations<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Frequency not reported</b>: Immune reconstitution syndrome, autoimmune disorders in the setting of immune reconstitution (e.g., Graves' disease, polymyositis, Guillain-Barre syndrome)<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Frequency not reported</b>: Higher serum parathyroid hormone levels</p>
<p></p>
<p>Efavirenz:</p>
<p>-Postmarketing reports: Gynecomastia<sup>[Ref]</sup></p><h3>Ocular</h3><p>Efavirenz:</p>
<p>-Postmarketing reports: Abnormal vision<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Symfi Lo (efavirenz / lamivudine / tenofovir)." Mylan Specialty, Morgantown, WV. </p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>What is the difference between HIV treatments Symfi and Symfi Lo?</li>
<li>What drugs are contained in the HIV treatment Symfi Lo?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Symfi Lo (efavirenz / lamivudine / tenofovir)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Generic Availability</li>
<li>Drug class: antiviral combinations</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Symfi Lo &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Symfi</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>HIV Infection</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to efavirenz / lamivudine / tenofovir: oral tablet</i></p><h3>General</h3><p>In a controlled trial with efavirenz, lamivudine, and tenofovir disoproxil fumarate (DF), the most common side effects were mild-to-moderate gastrointestinal events and dizziness.  Mild side effects (grade 1) were common and included dizziness, diarrhea, and nausea.</p><p></p><p>In a controlled trial with efavirenz (400 or 600 mg) in combination with fixed-dose emtricitabine-tenofovir DF, the most common side effects were mild-to-moderate gastrointestinal events, dizziness, abnormal dreams, and rash.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (14%)</p><p><b>Common</b> (1% to 10%): Dizziness</p><p><b>Uncommon</b> (0.1% to 1%): Peripheral neuropathy (included peripheral neuritis, neuropathy)</p><p></p><p>Efavirenz (with emtricitabine-tenofovir DF):</p><p>-Very common (10% or more): Dizziness (up to 35%), headache (up to 11%)</p><p>-Common (1% to 10%): Herpes zoster, somnolence</p><p></p><p>Efavirenz:</p><p>-Very common (10% or more): Central nervous system symptoms (53%), dizziness (28.1%)</p><p>-Common (1% to 10%): Impaired concentration, somnolence</p><p>-Postmarketing reports: Abnormal coordination, ataxia, cerebellar coordination and balance disturbances, convulsions, hypoesthesia, paresthesia, neuropathy, tremor, vertigo, tinnitus<sup>[Ref]</sup></p><p>Central nervous system (CNS) symptoms were reported in 53% of patients using efavirenz; these symptoms generally began the first or second day of therapy and often resolved after 2 to 4 weeks.  CNS symptoms (any grade, regardless of causality) included, but were not limited to, dizziness, insomnia, impaired concentration, somnolence, abnormal dreams, and hallucinations.  These symptoms were severe in 2% of patients; therapy was discontinued in 2.1% of patients due to these side effects.  After 4 weeks of therapy, CNS symptoms of at least moderate severity were reported in 5% to 9% of patients using efavirenz-containing regimens.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash event (included rash, pruritus, maculopapular rash, urticaria, vesiculobullous rash, pustular rash; 18%)</p><p></p><p>Efavirenz (with emtricitabine-tenofovir DF):</p><p>-Very common (10% or more): Rash event (included allergic dermatitis, drug hypersensitivity, generalized pruritus, eosinophilic pustular folliculitis, rash, erythematous rash, generalized rash, macular rash, maculopapular rash, morbilliform rash, papular rash, pruritic rash, vesicular rash, urticaria; up to 32%)</p><p>-Common (1% to 10%): Grade 3 to 4 rash</p><p></p><p>Efavirenz:</p><p>-Very common (10% or more): New-onset skin rash (26%)</p><p>-Uncommon (0.1% to 1%): Rash associated with blistering/moist desquamation/ulceration, grade 4 rash (e.g., erythema, multiforme, Stevens-Johnson syndrome)</p><p>-Postmarketing reports: Erythema multiforme, photoallergic dermatitis, Stevens-Johnson syndrome</p><p></p><p>Lamivudine:</p><p>-Postmarketing reports: Urticaria, alopecia, pruritus</p><p></p><p>Tenofovir DF:</p><p>-Postmarketing reports: Rash<sup>[Ref]</sup></p><p>Rashes associated with efavirenz were usually mild-to-moderate maculopapular skin eruptions.  The median time to onset of rash was 11 days.  In most patients who continued therapy, the rash resolved within 1 month.  Treatment was discontinued due to rash in 1.7% of patients.<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Elevated fasting cholesterol (19%)</p><p><b>Uncommon</b> (0.1% to 1%): Lipodystrophy, elevated fasting triglycerides</p><p><b>Frequency not reported</b>: Higher 1,25 vitamin D levels</p><p></p><p>Efavirenz (with emtricitabine-tenofovir DF):</p><p>-Common (1% to 10%): Cholesterol abnormal</p><p></p><p>Efavirenz:</p><p>-Postmarketing reports: Hypercholesterolemia, hypertriglyceridemia, redistribution/accumulation of body fat</p><p></p><p>Lamivudine:</p><p>-Postmarketing reports: Hyperglycemia, lactic acidosis, redistribution/accumulation of body fat</p><p></p><p>Tenofovir DF:</p><p>-Postmarketing reports: Lactic acidosis, hypokalemia, hypophosphatemia</p><p></p><p>Combination antiretroviral therapy:</p><p>-Frequency not reported: Redistribution/accumulation of body fat (including central obesity, dorsocervical fat enlargement, peripheral wasting, facial wasting, breast enlargement, "cushingoid appearance")<sup>[Ref]</sup></p><p>Elevated fasting cholesterol (greater than 240 mg/dL) and fasting triglycerides (greater than 750 mg/dL) have been reported in 19% and 1% of patients using efavirenz, lamivudine, and tenofovir DF, respectively.</p><p></p><p>Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) have been reported with the use of nucleoside analogs.</p><p></p><p>Hypokalemia and hypophosphatemia may occur as a result of proximal renal tubulopathy.<sup>[Ref]</sup></p><h3>Other</h3><p>False-positive urine cannabinoid test results have been observed with some screening assays in uninfected and HIV-infected subjects using efavirenz.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Pain (13%)</p><p><b>Common</b> (1% to 10%): Fever, asthenia</p><p></p><p>Efavirenz (with emtricitabine-tenofovir DF):</p><p>-Common (1% to 10%): Pyrexia, phosphorus abnormal</p><p></p><p>Efavirenz:</p><p>-Frequency not reported: False-positive urine cannabinoid test results</p><p>-Postmarketing reports: Asthenia, flushing</p><p></p><p>Lamivudine:</p><p>-Postmarketing reports: Weakness</p><p></p><p>Tenofovir DF:</p><p>-Postmarketing reports: Asthenia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Elevated creatine phosphokinase (12%)</p><p><b>Common</b> (1% to 10%): Back pain, arthralgia, myalgia</p><p><b>Frequency not reported</b>: Decreased bone mineral density, increased biochemical markers of bone metabolism (serum bone-specific alkaline phosphatase, serum osteocalcin, serum C telopeptide, urinary N telopeptide), clinically relevant fractures (excluding fingers and toes)</p><p></p><p>Efavirenz:</p><p>-Postmarketing reports: Arthralgia, myalgia, myopathy</p><p></p><p>Lamivudine:</p><p>-Postmarketing reports: Muscle weakness, elevated creatine phosphokinase, rhabdomyolysis</p><p></p><p>Tenofovir DF:</p><p>-Postmarketing reports: Rhabdomyolysis, osteomalacia (manifested as bone pain and which may contribute to fractures), muscular weakness, myopathy<sup>[Ref]</sup></p><p>Elevated creatine phosphokinase (males: greater than 990 units/L; females: greater than 845 units/L) has been reported in 12% of patients using efavirenz, lamivudine, and tenofovir DF.</p><p></p><p>Rhabdomyolysis, osteomalacia, muscular weakness, and myopathy may occur as a result of proximal renal tubulopathy.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (11%)</p><p><b>Common</b> (1% to 10%): Nausea, increased serum amylase, abdominal pain, dyspepsia, vomiting</p><p></p><p>Efavirenz (with emtricitabine-tenofovir DF):</p><p>-Common (1% to 10%): Diarrhea, vomiting, gastroenteritis</p><p></p><p>Efavirenz:</p><p>-Postmarketing reports: Constipation, malabsorption</p><p></p><p>Lamivudine:</p><p>-Frequency not reported: Pancreatitis</p><p></p><p>Tenofovir DF:</p><p>-Postmarketing reports: Pancreatitis, increased amylase, abdominal pain<sup>[Ref]</sup></p><p>Increased serum amylase (greater than 175 units/L) has been reported in 9% of patients using efavirenz, lamivudine, and tenofovir DF.</p><p></p><p>Pancreatitis (some cases fatal) has been reported in antiretroviral nucleoside-experienced pediatric patients using lamivudine alone or in combination with other antiretroviral agents.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Depression (11%)</p><p><b>Common</b> (1% to 10%): Anxiety, insomnia, abnormal dreams</p><p></p><p>Efavirenz (with emtricitabine-tenofovir DF):</p><p>-Common (1% to 10%): Insomnia, abnormal dreams, depression, sleep disorder, nightmare, anxiety</p><p></p><p>Efavirenz:</p><p>-Very common (10% or more): Insomnia (16.3%)</p><p>-Common (1% to 10%): Severe depression, abnormal dreams, hallucinations</p><p>-Uncommon (0.1% to 1%): Suicidal ideation, nonfatal suicide attempts, aggressive behavior, paranoid reactions, manic reactions</p><p>-Postmarketing reports: Aggressive reactions, agitation, delusions, emotional lability, mania, neurosis, paranoia, psychosis, suicide, catatonia<sup>[Ref]</sup></p><h3>Genitourinary</h3><p>Hematuria (greater than 100 RBC/high power field) has been reported in 7% of patients using efavirenz, lamivudine, and tenofovir DF.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Hematuria</p><p></p><p>Tenofovir DF:</p><p>-Postmarketing reports: Proteinuria, polyuria<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Elevated AST (males: greater than 180 units/L; females: greater than 170 units/L) and ALT (males: greater than 215 units/L; females: greater than 170 units/L) have been reported in 5% and 4% patients using efavirenz, lamivudine, and tenofovir DF, respectively.</p><p></p><p>Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) have been reported with the use of nucleoside analogs.</p><p></p><p>Severe acute exacerbations of hepatitis B have been reported in patients coinfected with HIV-1 and hepatitis B virus after discontinuation of lamivudine or tenofovir DF.</p><p></p><p>Hepatic decompensation (some fatal) has been reported in patients coinfected with HIV-1 and hepatitis C receiving combination antiretroviral therapy for HIV-1 and interferon alfa with or without ribavirin.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Elevated AST, elevated ALT</p><p></p><p>Efavirenz (with emtricitabine-tenofovir DF):</p><p>-Common (1% to 10%): ALT abnormal, AST abnormal</p><p>-Uncommon (0.1% to 1%): Bilirubin abnormal</p><p></p><p>Efavirenz:</p><p>-Postmarketing reports: Increased hepatic enzymes, hepatic failure, hepatitis (including fulminant hepatitis progressing to liver failure requiring transplantation or resulting in death)</p><p></p><p>Lamivudine:</p><p>-Postmarketing reports: Hepatic steatosis, posttreatment exacerbation of hepatitis B</p><p></p><p>Tenofovir DF:</p><p>-Postmarketing reports: Hepatic steatosis, hepatitis, increased liver enzymes (most commonly AST, ALT, GGT)</p><p></p><p>Combination antiretroviral therapy:</p><p>-Frequency not reported: Hepatic decompensation<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Decreased neutrophils (less than 750/mm3) has been reported in 3% of patients using efavirenz, lamivudine, and tenofovir DF.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Decreased neutrophils</p><p></p><p>Efavirenz (with emtricitabine-tenofovir DF):</p><p>-Common (1% to 10%): Neutrophils abnormal</p><p></p><p>Lamivudine:</p><p>-Postmarketing reports: Anemia (including pure red cell aplasia and severe anemias progressing on therapy)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Pneumonia</p><p></p><p>Efavirenz (with emtricitabine-tenofovir DF):</p><p>-Common (1% to 10%): Upper respiratory tract infection, nasopharyngitis</p><p></p><p>Efavirenz:</p><p>-Postmarketing reports: Dyspnea</p><p></p><p>Tenofovir DF:</p><p>-Postmarketing reports: Dyspnea<sup>[Ref]</sup></p><h3>Renal</h3><p>Tenofovir DF:</p><p>-Postmarketing reports: Renal insufficiency, acute renal failure, renal failure, acute tubular necrosis, Fanconi syndrome, proximal renal tubulopathy, interstitial nephritis (including acute cases), nephrogenic diabetes insipidus, increased creatinine<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Efavirenz:</p><p>-Postmarketing reports: Allergic reactions</p><p></p><p>Lamivudine:</p><p>-Postmarketing reports: Anaphylaxis</p><p></p><p>Tenofovir DF:</p><p>-Postmarketing reports: Allergic reaction (including angioedema)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Efavirenz:</p><p>-Frequency not reported: QTc prolongation</p><p>-Postmarketing reports: Palpitations<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Frequency not reported</b>: Immune reconstitution syndrome, autoimmune disorders in the setting of immune reconstitution (e.g., Graves' disease, polymyositis, Guillain-Barre syndrome)<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Frequency not reported</b>: Higher serum parathyroid hormone levels</p><p></p><p>Efavirenz:</p><p>-Postmarketing reports: Gynecomastia<sup>[Ref]</sup></p><h3>Ocular</h3><p>Efavirenz:</p><p>-Postmarketing reports: Abnormal vision<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Symfi Lo (efavirenz / lamivudine / tenofovir)." Mylan Specialty, Morgantown, WV. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What is the difference between HIV treatments Symfi and Symfi Lo?</li>
<li>What drugs are contained in the HIV treatment Symfi Lo?</li>
</ul><h2>More about Symfi Lo (efavirenz / lamivudine / tenofovir)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Generic Availability</li>
<li>Drug class: antiviral combinations</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Symfi Lo &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>HIV Infection</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>